FXYD3 and diabetic cardiomyopathy: In our present study, MVT-treatment in diabetic rats resulted in opposite gene expression changes in case of some aforementioned genes (e.g. caspase recruitment domain family, member 9 (Card9); adrenoceptor alpha 1d (adra1d); cytochrome P450, family 26, subfamily B, polypeptide 1 (Cyp26b1; FXYD domain containing ion transport regulator 3 (Fxyd3); ATPase, H+Transporting, Lysosomal 13 kDa, V1 Subunit G21 (Atp6v1g2); etc.)showing a beneficial effect of MVT-treatment on the development of diabetic cardiomyopathy (Tables 2 and 5, Fig. 2).